Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ahlers, J. D.
Right arrow Articles by Berzofsky, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahlers, J. D.
Right arrow Articles by Berzofsky, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 13, No. 7, 897-908, July 2001
© 2001 Japanese Society for Immunology

Mechanisms of cytokine synergy essential for vaccine protection against viral challenge

Jeffrey D. Ahlers, Igor M. Belyakov, So Matsui and Jay A. Berzofsky

Molecular Immunogenetics and Vaccine Research Section Metabolism Branch, National Cancer Institute, National Institute of Health, Bldg 10, Rm 6B-12 (MSC#1578), Bethesda, MD 20892, USA

Correspondence to: J. A. Berzofsky

The ability of cytokines to steer CD4+ Th cell responses toward a Th1 or Th2 phenotype and enhance the magnitude of both CD8+ cytotoxic T lymphocytes (CTL) and antibody responses has clearly been demonstrated by our lab and others, but the influence of cytokines on protective immune responses is much less clear. Here we show an essential role for CD4+ Th1 helper cell induction and IFN-{gamma} production in protection from viral challenge with a recombinant vaccinia virus expressing HIV-1MN viral envelope glycoprotein gp160. Complete protection from viral challenge is achieved only when the triple combination of exogenous cytokines granulocyte macrophage colony stimulating factor (GM-CSF), IL-12 and tumor necrosis factor (TNF)-{alpha} are co-administered with the peptide vaccine. In vivo depletion of CD4+ cells or immunization of IFN-{gamma}-deficient mice abrogates protection. GM-CSF, IL-12 and TNF-{alpha} also synergize for the enhanced induction of CTL; however, adoptive transfer of a CD8+ CTL line afforded only partial protection in this viral challenge model. As a possible mechanism of in vivo protection we show that GM-CSF increases the percentage and activity of antigen-presenting dendritic cells in draining lymph nodes where the immune response is initiated. We further demonstrate synergy between IL-12 and the proinflammatory cytokine TNF-{alpha} in driving IFN-{gamma} production. Thus, a combination of IL-12 and TNF-{alpha} is essential for the optimal development of Th1 responses and help for CTL induction in BALB/c mice, and is complemented by a third cytokine, GM-CSF, which enhances antigen presentation.

Keywords: cytokines, cytotoxic T lymphocyte, Th1 cells, viral immunity

Transmitting editor: H. Wigzell


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int ImmunolHome page
I. M. Belyakov, S. Kozlowski, M. Mage, J. D. Ahlers, L. F. Boyd, D. H. Margulies, and J. A. Berzofsky
Role of {alpha}3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs
Int. Immunol., December 1, 2007; 19(12): 1413 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. M. Belyakov, D. Isakov, Q. Zhu, A. Dzutsev, and J. A. Berzofsky
A Novel Functional CTL Avidity/Activity Compartmentalization to the Site of Mucosal Immunization Contributes to Protection of Macaques against Simian/Human Immunodeficiency Viral Depletion of Mucosal CD4+ T Cells
J. Immunol., June 1, 2007; 178(11): 7211 - 7221.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. S. Kornbluth and G. W. Stone
Immunostimulatory combinations: designing the next generation of vaccine adjuvants
J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Andreakos, R. O. Williams, J. Wales, B. M. Foxwell, and M. Feldmann
Activation of NF-{kappa}B by the intracellular expression of NF-{kappa}B-inducing kinase acts as a powerful vaccine adjuvant
PNAS, September 26, 2006; 103(39): 14459 - 14464.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. Botten, J. Alexander, V. Pasquetto, J. Sidney, P. Barrowman, J. Ting, B. Peters, S. Southwood, B. Stewart, M. P. Rodriguez-Carreno, et al.
Identification of Protective Lassa Virus Epitopes That Are Restricted by HLA-A2.
J. Virol., September 1, 2006; 80(17): 8351 - 8361.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. W. Hodge, M. Chakraborty, C. Kudo-Saito, C. T. Garnett, and J. Schlom
Multiple Costimulatory Modalities Enhance CTL Avidity
J. Immunol., May 15, 2005; 174(10): 5994 - 6004.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. T. Snyder, I. M. Belyakov, A. Dzutsev, F. Lemonnier, and J. A. Berzofsky
Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8+ T-Cell Peptide Epitope of Vaccinia and Variola Viruses
J. Virol., July 1, 2004; 78(13): 7052 - 7060.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. S. Sabel, J. Skitzki, L. Stoolman, N. K. Egilmez, E. Mathiowitz, N. Bailey, W.-J. Chang, and A. E. Chang
Intratumoral IL-12 and TNF-{alpha}-Loaded Microspheres Lead To Regression of Breast Cancer and Systemic Antitumor Immunity
Ann. Surg. Oncol., February 1, 2004; 11(2): 147 - 156.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Daftarian, S. Ali, R. Sharan, S. F. Lacey, C. La Rosa, J. Longmate, C. Buck, R. F. Siliciano, and D. J. Diamond
Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge
J. Immunol., October 15, 2003; 171(8): 4028 - 4039.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Okazaki, C. D. Pendleton, F. Lemonnier, and J. A. Berzofsky
Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressing HIV-1 Antigen
J. Immunol., September 1, 2003; 171(5): 2548 - 2555.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. D. Ahlers, I. M. Belyakov, M. Terabe, R. Koka, D. D. Donaldson, E. K. Thomas, and J. A. Berzofsky
A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L
PNAS, October 1, 2002; 99(20): 13020 - 13025.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
J. D. Ahlers, I. M. Belyakov, S. Matsui, and J. A. Berzofsky
Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-{alpha} synergize for IL-12R expression at low antigen dose
Int. Immunol., November 1, 2001; 13(11): 1433 - 1442.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.